Standard: this guide onlyAll-Access Lifetime: all 45 guides + downloadsEducational content only
GHRP-6 Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Reported in research contexts for growth hormone release, appetite stimulation, and body-composition studies
Commonly reported range
100-300 mcg per injection (community-reported saturation dose ~1 mcg/kg)
Route reported
Subcutaneous injection (research settings)
Reported frequency
2-3 times daily, on an empty stomach
Reported cycle
8-12 weeks in community reports
Plasma half-life
Reported ~15-20 minutes (short); some sources cite a terminal phase up to ~2.5 hours
Regulatory status
Not FDA-approved for any use; research-use only; WADA-prohibited (S2) in and out of competition
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
GHRP-6 is a synthetic hexapeptide that acts as a growth hormone secretagogue by binding the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. Through this receptor it is reported to stimulate the pituitary to release growth hormone (GH) in pulses and to promote GH release with a mechanism distinct from GHRH analogues. Because it activates the ghrelin pathway, GHRP-6 is also reported to strongly stimulate appetite via neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus. As an early-generation GHRP, it is reported in research to also raise cortisol and prolactin to some degree, unlike more selective later secretagogues. These are described mechanisms from research and community reports, not statements of clinical benefit.
Researched effects
In research and community reports, GHRP-6 is associated with increased pulsatile growth hormone release, pronounced appetite stimulation, and interest in recovery and body-composition contexts; it is often studied alongside GHRH analogues for a synergistic GH pulse. These are research findings and community-reported observations, not guaranteed outcomes, and GHRP-6 is not approved to treat, cure, or prevent any condition.
Evidence & regulatory status
Evidence: GHRP-6 has been characterized in pharmacology and endocrinology research as a ghrelin-receptor (GHS-R1a) agonist that stimulates pulsatile GH release and appetite; most data are preclinical or early human dose-response studies rather than large clinical trials.
Regulatory: GHRP-6 has no FDA-approved use and no approved drug product; the FDA classified it as a Category 2 bulk drug substance (2023). WADA prohibits it under Section S2 both in- and out-of-competition.
Research-use: Sold and handled as a research chemical only; not intended for human or veterinary therapeutic use.
Dosage — reported ranges (overview)
The figures below are examples of what is reported in the community and dose-response literature, not a recommendation. A commonly cited community reference is a saturation dose of roughly 1 mcg per kg of body weight, translating to around 100 mcg per injection for many adults, with reported per-injection amounts of 100-300 mcg taken two to three times daily on an empty stomach (a bedtime dose is often prioritized to align with nocturnal GH release). Reported cycles run about 8-12 weeks. None of this constitutes a personal dose or medical guidance.
The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.
Reconstitution — bac-water math
Reconstitution is concentration math only, not a personal dose. GHRP-6 is dosed in micrograms (mcg), so it helps to work in mcg/mL. For a V-mg vial reconstituted with W mL of bacteriostatic water, concentration = (V x 1000) / W mcg per mL, and on a U-100 insulin syringe the units for a dose of D mcg = round(D / concentration x 100). Worked example: a representative 5 mg vial reconstituted with 2 mL of bacteriostatic water gives (5 x 1000) / 2 = 2500 mcg/mL. A 100 mcg example dose is then 100 / 2500 x 100 = 4 units on a U-100 syringe.
Bac water added
Concentration
100 mcg dose
300 mcg dose
1 mL
5000 mcg/mL (5 mg/mL)
2 units
6 units
2 mL
2500 mcg/mL (2.5 mg/mL)
4 units
12 units
3 mL
~1667 mcg/mL (~1.67 mg/mL)
6 units
18 units
This is concentration math, not a dose recommendation.
Pre-fills example values. Every field remains editable.
The amount printed on the vial or listed on a product page.
mL
Liquid volume used for the concentration calculation.
The mass amount to convert into liquid volume for this math example.
4. Insulin syringe size
Your result
Syringe-unit reading
10 units
= 0.1 mL · 250 mcg target amount
Concentration
2.5mg/mL
Per insulin unit
25mcg
Portions per vial
20
Volume
0.1mL
This calculator is an educational tool for laboratory and research math only. The peptides referenced are research compounds not intended for human or veterinary use, and example values are not medical advice or personal-use instructions. Follow applicable research protocols and regulations.
How the calculator works
Concentration
peptide ÷ liquid
Total peptide divided by liquid volume gives the concentration per mL.
Volume
target ÷ concentration
The target mass divided by concentration gives the liquid volume.
Syringe units
volume × 100
For insulin units, 100 units equals 1 mL, so mL is multiplied by 100.
Worked example: A 5 mg vial plus 2 mL liquid creates a 2.5 mg/mL concentration. A 250 mcg target amount equals 0.1 mL, or 10 insulin units. The vial contains 20 such portions.
Frequently asked questions
How much bacteriostatic water should I enter?+
There is no single calculator-default amount. The liquid volume controls concentration: more liquid creates a less concentrated solution and a larger volume reading for the same target amount; less liquid creates a more concentrated solution and a smaller volume reading.
How do insulin syringe units relate to mL?+
For this math tool, 100 insulin units equals 1 mL, and 1 unit equals 0.01 mL. The 0.3 mL, 0.5 mL, and 1.0 mL options change capacity, not the unit-to-mL relationship.
What is the difference between mg, mcg, and units?+
Milligrams and micrograms measure peptide mass: 1 mg = 1,000 mcg. Syringe units measure liquid volume. Reconstitution math connects mass and volume by using concentration.
Does changing the liquid volume change the total peptide in the vial?+
No. The total peptide amount entered for the vial remains fixed. Changing the liquid volume only changes concentration and the resulting volume shown by the calculator.
Injection / administration basics
In research settings GHRP-6 is reported to be administered subcutaneously, typically on an empty stomach (often 20-30 minutes before eating) because food, especially fats and carbohydrates, is reported to blunt the GH response. Reconstitution uses bacteriostatic water added slowly against the vial wall, with gentle swirling rather than shaking to avoid denaturing the peptide. This describes reported handling practices, not medical instructions.
Half-life & frequency rationale
GHRP-6 is reported to have a short plasma half-life of approximately 15-20 minutes, which is why multiple daily injections are described in community protocols to maintain repeated GH pulses; some pharmacokinetic sources cite a longer terminal elimination phase up to roughly 2.5 hours reflecting slower clearance from peripheral compartments.
Side effects, safety & contraindications
Human safety data are limited, and GHRP-6 is not an approved drug. As an early-generation GHRP, it is reported in research and community sources to cause strong appetite/hunger, and to raise cortisol and prolactin more than selective secretagogues; other reported effects include water retention, tingling or numbness in the hands, temporary drops in blood sugar, flushing, head-rush sensations, and injection-site reactions. These are reported observations, not a complete safety profile, and long-term human safety has not been established.
Stacking — overview
In community reports, GHRP-6 is most often combined with a GHRH analogue to amplify the growth hormone pulse, since a GHRP plus a GHRH agent are reported to act synergistically on pulse amplitude and frequency. Some users choose GHRP-6 specifically when appetite stimulation is desired, whereas more selective secretagogues are chosen to avoid the hunger, cortisol, and prolactin effects. The following are commonly reported pairings, described as examples rather than recommendations.
GH Pulse Stack
GHRP-6 + CJC-1295 (Mod GRF 1-29) — the classic GHRP plus GHRH-analogue pairing reported for a stronger, synergistic GH pulse
Appetite & Recovery Stack
GHRP-6 + Ipamorelin — combining GHRP-6's appetite drive with a more selective secretagogue in community reports
GHRP-6 + Sermorelin or Tesamorelin — pairing with GHRH analogues reported for GH-axis support
Storage & handling
Lyophilized (powder): reported stable refrigerated at 2-8 C, and can be kept frozen for longer-term storage; keep away from light and moisture.
Reconstituted (liquid): reported to be kept refrigerated at 2-8 C and used within about 2-4 weeks; do not freeze after reconstitution and avoid shaking.
References
Information compiled from peptide pharmacology and endocrinology literature on growth hormone secretagogues, the WADA Prohibited List (Section S2), FDA bulk drug substance classifications, and publicly available community-reported protocols; presented for educational research use only, not medical advice.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Quick answers about guide scope, access, and educational use context.
What is GHRP-6 and how does it work?
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide growth hormone secretagogue. It is reported to bind the ghrelin receptor (GHS-R1a) and stimulate pulsatile growth hormone release, while also strongly stimulating appetite. This is described mechanism from research, not a claim of clinical benefit.
How is GHRP-6 different from ipamorelin?
Both are ghrelin-receptor agonists, but GHRP-6 is an early-generation GHRP reported to raise cortisol, prolactin, and appetite alongside GH, whereas ipamorelin is reported to be more selective with fewer of those effects. Some users pick GHRP-6 specifically for the appetite stimulation. These are reported differences, not recommendations.
What doses are reported for GHRP-6?
Community and dose-response reports commonly cite a saturation dose near 1 mcg/kg, roughly 100 mcg per injection for many adults, with 100-300 mcg used two to three times daily on an empty stomach. These are reported examples for education only, not a personal dose or medical advice.
Is GHRP-6 legal or FDA-approved?
GHRP-6 has no FDA-approved use and no approved drug product; it is handled as a research chemical only. It is also prohibited by WADA under Section S2 both in and out of competition. Always follow the laws and regulations that apply to you.
How do I reconstitute GHRP-6?
Reconstitution is concentration math only. Adding bacteriostatic water to the lyophilized vial and computing mcg/mL lets you convert an example dose to insulin-syringe units. For a 5 mg vial with 2 mL water you get 2500 mcg/mL, so a 100 mcg example is 4 units on a U-100 syringe. This is not a personal dose.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
